Mortality trends in multiple myeloma after the introduction of novel therapies in the United StatesMoritz Binder, Shaji Kumar, Bharat Nandakumar et al.|Leukemia|2021Cited by 105
Enhancing the R‐ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cellsWilson I. Gonsalves, Shaji Kumar, Dragan Jevremović et al.|American Journal of Hematology|2019Cited by 63
“Real-life” data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma—the Mayo Clinic experienceIuliana Vaxman, Morie A. Gertz, Angela Dispenzieri et al.|Blood Cancer Journal|2021Cited by 49
MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patientsPatrick Mellors, Angela Dispenzieri, Surendra Dasari et al.|Blood Cancer Journal|2021Cited by 47
Clinical Activity of Single Dose Systemic Oncolytic VSV Virotherapy in Patients with Relapsed Refractory T-Cell LymphomaJoselle Cook, Martha Q. Lacy, Kah Whye Peng et al.|Blood Advances|2022Cited by 44